PURPOSE: To evaluate the prognostic significance of excision repair cross-complementation group 1 (ERCC1) expression in head and neck carcinoma patients treated with definitive radiotherapy (DR) or adjuvant radiotherapy (AR). METHODS: ERCC1 expression was assessed by immunohistochemical staining. A total of 48 patients were assessed. RESULTS: High ERCC1 expression was found in 23 patients (48 %). More ERCC1-positive tumours were detected in patients treated with DR than in patients treated with AR (73 vs. 36 %, respectively, p = 0.03). ERCC1 expression had no impact on overall survival neither in the whole cohort of patients (p = 0.16) nor in each particular treatment group (AR p = 0.98; DR p = 0.21). CONCLUSIONS: ERCC1 expression had no predictive value in head and neck carcinoma patients treated with DR or AR. There might be difference in ERCC1 positivity that comes out of whether the assessment is done on biopsy or surgical specimens.
PURPOSE: To evaluate the prognostic significance of excision repair cross-complementation group 1 (ERCC1) expression in head and neck carcinomapatients treated with definitive radiotherapy (DR) or adjuvant radiotherapy (AR). METHODS:ERCC1 expression was assessed by immunohistochemical staining. A total of 48 patients were assessed. RESULTS: High ERCC1 expression was found in 23 patients (48 %). More ERCC1-positive tumours were detected in patients treated with DR than in patients treated with AR (73 vs. 36 %, respectively, p = 0.03). ERCC1 expression had no impact on overall survival neither in the whole cohort of patients (p = 0.16) nor in each particular treatment group (AR p = 0.98; DR p = 0.21). CONCLUSIONS:ERCC1 expression had no predictive value in head and neck carcinomapatients treated with DR or AR. There might be difference in ERCC1 positivity that comes out of whether the assessment is done on biopsy or surgical specimens.
Authors: Y Shirota; J Stoehlmacher; J Brabender; Y P Xiong; H Uetake; K D Danenberg; S Groshen; D D Tsao-Wei; P V Danenberg; H J Lenz Journal: J Clin Oncol Date: 2001-12-01 Impact factor: 44.544
Authors: R G Sargent; J L Meservy; B D Perkins; A E Kilburn; Z Intody; G M Adair; R S Nairn; J H Wilson Journal: Nucleic Acids Res Date: 2000-10-01 Impact factor: 16.971
Authors: Corinne M Doll; Michael Prystajecky; Misha Eliasziw; Alexander C Klimowicz; Stephanie K Petrillo; Peter S Craighead; Desiree Hao; Roman Diaz; Susan P Lees-Miller; Anthony M Magliocco Journal: Radiother Oncol Date: 2010-10-09 Impact factor: 6.280
Authors: L Taillade; F Penault-Llorca; T Boulet; P Fouret; S Michiels; E Taranchon; G Mountzios; P Validire; J Domont; P Girard; D Grunenwald; T Le Chevalier; J-C Soria Journal: Ann Oncol Date: 2007-03-12 Impact factor: 32.976
Authors: Lucianne Maia Costa Lima; Ludmilla Regina de Souza; Thiago Fonseca da Silva; Camila Santos Pereira; André Luiz Sena Guimarães; Alfredo Maurício Batista de Paula; Heloisa de Andrade Carvalho Journal: Histopathology Date: 2011-12-16 Impact factor: 5.087